The Role of Biomarkers in Gastric Cancers

Video

Maria Svensson, MD, Lund University, discusses the importance of biomarkers in the field of gastric cancers. In a recent study, she used evidence of mismatch repair to determine prognosis of the patients.

Maria Svensson, MD, Lund University, discusses the importance of biomarkers in the field of gastric cancers. In a recent study, she used evidence of mismatch repair (MMR) to determine prognosis of the patients.

Recent Videos
Related Content
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer

Jordyn Sava
March 31st 2025
Article

Read More

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma

Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma

Jordyn Sava
March 19th 2025
Article

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.

Read More

Amivantamab/Lazertinib Efficacy in EGFR+ NSCLC Sustained in MARIPOSA Follow-Up

Amivantamab/Lazertinib Efficacy in EGFR+ NSCLC Sustained in MARIPOSA Follow-Up

Jordyn Sava
March 18th 2025
Article

Shirish M. Gadgeel, MD, discussed long-term data from the MARIPOSA trial of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

Read More